Published: Jul 07, 2021 By Alex Keown
Collaborations are part of the life’s blood of clinical development as biopharma and life sciences companies partner and pool resources to develop novel therapies and treatments for a myriad of diseases.
This morning, multiple companies announced clinical and strategic collaborations.
PureTech Health to Harness BeiGene’s Checkpoint Inhibitor
Boston-based PureTech Health plc and
forged an alliance to assess the combination of BeiGene’s experimental checkpoint inhibitor tislelizumab with
PureTech s LYT-200, an experimental monoclonal antibody targeting galectin-9, as a potential treatment for difficult-to-treat solid tumor indications that are associated with poor survival rates. Galectin-9 is a widely expressed immune modulator in multiple tumor types that are difficult-to-treat tumor types.